Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Diamond

Podiatrist, Foot Surgery Bethlehem, PA Doctor of Podiatric Medicine

NPI 1588661284 CMS profile 298873

303 W Broad Street, Bethlehem, PA 18018

Open in the dashboard

General payments

$1,103

17 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Diamond of Bethlehem, PA is reported in the CMS Open Payments database as having received $1,103 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $294 5
2024 General $265 5
2023 General $154 2
2022 General $176 2
2019 General $214 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Diamond
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Robert Diamond were reported at $294. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Robert Diamond Podiatrist, Foot Surgery median Middle half National median
2019 $214 $167 $67–$484 $163
2020 $0 $114 $40–$323 $114
2021 $0 $171 $57–$502 $132
2022 $176 $196 $66–$556 $149
2023 $154 $187 $78–$466 $160
2024 $265 $190 $78–$557 $164
2025 $294 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novus Surgical Consultants $363 7 payments
  2. Stryker Corporation $272 3 payments
  3. Novus Surgical Solutions LLC $144 1 payment
  4. Pacira Pharmaceuticals Incorporated $125 1 payment
  5. DePuy Synthes Sales Inc. $77 1 payment
  6. Trice Medical, Inc. $62 1 payment
  7. Smith+Nephew, Inc. $32 1 payment
  8. Integra LifeSciences Corporation $16 1 payment
  9. Bioventus LLC $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,103 17 payments
Products named General payments · program years 2019–2025
  1. INFINITY ADAPTIS $133 1 payment
  2. EXPAREL Pain Management $125 1 payment
  3. PHALINX $125 1 payment
  4. EXPAREL Spine $77 1 payment
  5. EVOS $32 1 payment
  6. EVOS MINI $32 1 payment
  7. Integra Recon-Skin And Wound $16 1 payment
  8. Integra Recon-Skin And Wound $16 1 payment
  9. Integra Recon-Skin And Wound $16 1 payment
  10. INTEGRA DERMAL REGENERATION TEMPLATE $16 1 payment
  11. Other $42 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

553

Median for Podiatry: 160

Drug cost

$6,462

Median for Podiatry: $2,368

Branded share of claims

2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 261 $3,743
Duloxetine Hcl Generic 22 $656
Triamcinolone Acetonide Generic 16 $405
Terbinafine Hcl Generic 44 $381
Mupirocin Generic 53 $370
Meloxicam Generic 91 $355
Doxycycline Hyclate Generic 22 $172
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 11 $141
Cephalexin Generic 14 $136
Methylprednisolone Generic 19 $104

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$96,925

Of which drugs: $162

Medicare patients

724

Average age 75

Services billed

2,171

421 women, 303 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Chronic kidney disease 41%
Diabetes 40%
Ischemic heart disease 28%
Depression 23%
Atrial fibrillation 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 223 $162

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record